White & Case (New York)

Kristen O’Shaughnessy

White & Case (New York)
Lawyer (Partner)

Kristen O’Shaughnessy is a Partner in White & Case’s New York office and a member of the Firm’s global Competition Group. Ms. O’Shaughnessy’s practice focuses on complex antitrust litigation and counseling. She regularly represents clients in the pharmaceutical industry. Ms. O’Shaughnessy is Secretary of the Women’s Network at White & Case, involved in coordinating female mentoring, networking events, and community outreach. Prior to joining White & Case, Ms. O’Shaughnessy worked in Thailand advising clients on international intellectual property issues, including counseling the Thai Department of Intellectual Property on compliance with the Madrid Protocol and assisting a major pharmaceutical company with its global patent litigation strategy. Ms. O’Shaughnessy holds a degree in engineering from Northwestern University.

Distinctions

Linked authors

White & Case (Brussels)
White & Case (Washington)
White & Case (New York)
White & Case (Washington)
White & Case (New York)

Articles

2101 Bulletin

Michael Gallagher, Kristen O’Shaughnessy, Kathryn Jordan Mims, Kevin Adam, Jaclyn Phillips The US President Joe Biden publishes an executive order containing 72 initiatives to address competition concerns in several industries, including pharmaceuticals, biotech, and healthcare

636

Citing concerns about growing consolidation, reduced competition, and increasing prices, President Biden issued on July 9, 2021 a sweeping Executive Order containing 72 initiatives to address competition concerns in a number of industries, including pharmaceuticals, biotech, and healthcare. In (...)

Mark J. Gidley, George Paul, Jack E. Pace, Kathryn Jordan Mims, Kristen O’Shaughnessy, Kevin Adam, Jaclyn Phillips, Abdul Hafiz, Erin McNamee The US President Joe Biden signs an executive order instructing more than a dozen federal agencies to promptly tackle some of the most pressing competition problems across the national economy

502

A new Executive Order signed by President Biden includes 72 initiatives instructing more than a dozen federal agencies, including the US Department of Justice and the Federal Trade Commission, to, according to the White House’s Fact Sheet, "promptly tackle some of the most pressing competition (...)

Mark J. Gidley, Kathryn Jordan Mims, Kristen O’Shaughnessy, Erin McNamee, Kevin Adam, Jaclyn Phillips, Abdul Hafiz, Tal Marnin The US President Joe Biden signs an executive order which includes 72 initiatives aimed at enhancing competition and a directive encouraging the US FTC to ban or limit employee non-compete agreements

155

On Friday, July 9, 2021, President Biden signed Executive Order 14036, Promoting Competition in the American Economy, which includes—among 72 initiatives aimed at enhancing competition in the US—a directive encouraging the Federal Trade Commission to ban or limit employee non-compete agreements. (...)

Jack E. Pace, Kristen O’Shaughnessy, Robert Milne, Peter J. Carney, Michael Gallagher, Mark J. Gidley, Kevin Adam The US Congress proposes a package of bills on drug pricing, including changes to the treatment of reverse payments, product hopping, sham petitions, and patent dancing

159

What’s next for drug pricing in the US? Proposals to alter antitrust and patent laws may signal a renewed focus on drug pricing by federal lawmakers, while the growing web of state laws is expected to increase compliance challenges for the pharmaceutical industry. What’s changing? A new (...)

Mark J. Gidley, Noah A. Brumfield, Jack E. Pace, Kristen O’Shaughnessy, Dan Grossbaum, Bryan D. Gant The US State of California becomes the first State to enact legislation rendering certain pharmaceutical patent litigation settlement agreements presumptively anticompetitive

124

This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. On October 7, 2019, California became the first state to enact legislation— Assembly Bill 824 (“AB 824”)—rendering certain pharmaceutical patent litigation settlement (...)

Send a message